ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 19 of 61
JMBS 2018, 3(5): 94–99
Clinical Medicine

The Use of Nitroglycerin and Dobutamine in Intensive Therapy of Cancer Patients with Upper Vena Cava Syndrome

Krutko E. M., Pilipenko S. A.

The purpose of the study was to determine the effectiveness of prescribing dobutamine and nitroglycerin in intensive therapy of cerebral and cardio-hemodynamic disorders in the syndrome of the inferior vena cava in cancer patients. Material and methods. We carried out a survey of 25 cancer patients diagnosed with lung cancer, which was complicated by the syndrome of the upper vena cava. These patients were treated at the department of anesthesiology with beds for intensive care of the SI "Grigoriev Institute of Medical Radiology of the National Academy of Medical Sciences of Ukraine ". Before the operation, the patients were examined by clinical and instrumental methods for the diagnosis of cerebral and cardio-hemodynamic disorders (cerebral blood damage, as well as complaints of shortness of breath, cramping, coughing). In order to evaluate the presence of cerebral and cardio-hemodynamic disorders in patients, an analysis of the level of enzymes of the neuron-specific enolase (NSA) and glycolysis (glycerol-3-phosphate dehydrogenase, glyceraldehyde-phosphate-hydrogenase) was performed 3 days before the operation. Results and discussion. The problem was solved in the following way: in the standard scheme of treatment of cerebral and cardioghemmodynamic disorders in upper vena cava syndrome, which includes preoperative medication with cardiovascular inotropic agents, in particular, dobutamine, diluted in 0.9% sodium chloride solution, for three days to conduct two parallel operations intravenous infusion of 250 mg dobutamine administration with speed of 15-18 mg / kg / min, while 1% solution of nitroglycerin with the speed of introduction of 30-34 mg / min, while the keel of its infusion depends on the specific enzyme neuron-enolazy and glycolysis, including glycerol-3-phosphate and glyceraldehyde phosphate dehydrogenase. Simultaneous use of two parallel intravenous infusions of dobutamine and nitroglycerin, can reduce the disadvantages of each individual drug and enhance their positive joint action, reduce and prevent the emergence of cerebral and cardio-hemodynamic disorders, thereby preparing the patient for surgery. The presented set of features is optimal for the treatment of cerebral and cardio-hemodynamic disorders. It allows to provide a new technical result, in particular, to reduce the severity of cerebral and cardio-hemodynamic disorders in patients in the preoperative period, which helps them to delay surgical intervention. Conclusions. The question of adequate timely correction of central hemodynamic disorders is one of the key factors in the treatment of patients in intensive care units. Preoperative preparation of patients with SVPV includes, first of all, measures to improve the safety of surgical intervention and the favorable flow of the process in the immediate postoperative period.

Keywords: upper ventricular vein syndrome, neuronspecific enolase, enzymes glycolysis, oncopathology, intensive therapy, dobutamine, nitroglycerin

Full text: PDF (Ukr) 205K

  1. Procenko SA, Novik AV. Sindrom verhnej poloj veny. Prakticheskayao nkologiya. 2009; 7 (2): 108-12. [Russian]
  2. Hestopalova S. Terapevtichna pіdgotovka pacієntіv dooperativnogo lіkuvannya v onkohіrurgії. Klіnіchna praktika. 2013; 3 (15): 73-9. [Ukrainian]
  3. Suslina ZA, Varakin YuYa, Vereshchagіn NV. Sudinnі zahvoryuvannya golovnogo mozku. Epіdemіologіya. Osnovi profіlaktiki. M: MEDpress-іnform, 2009. 352 s. [Russian]
  4. Tochilo SA, Nikiforova YuG, Reznіkov MV. Zastosuvannya іnvazivnogo monіtoringu gemodinamіki u pacієnta z kardіogennijm shokom. Problemi zdorov'ya ta ekologії. 2015; 2 (44): 90-4. [Ukrainian]
  5. Vladika AS, Suslov VV, Tarabrin OA. Іnfuzіjna terapіya pri kritichnih stanah, K: Logos, 2010. 274 s. [Ukrainian]
  6. Єremenko AA. Zastosuvannya dobutamіnu v klіnіchnіj prakticі. Atmosfera. Novini kardіologії. 2009; 3: 31-4. [Ukrainian]
  7. Gіlyarov MYu. Zastosuvannya dobutamіnu v kardіologіchnіj prakticі. Racіonal'na farmakoterapіya v kardіologії. 2008; 5: 67-70. [Ukrainian]
  8. Burduli NM. Sindrom verhnej poloj veny. Klinicheskaya medicina. 2015; 93 (12): 61-3. [Russian]
  9. Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ, Thakkar R, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013; 1 (2): 103–11.
  10. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, et al. Levosimendan vsdobutamine for patients with acute decompensated heart failure:the SURVIVE Randomized Trial. JAMA. 2007; 297 (17): 1883–91.
  11. Bergh CH, Andersson B, Dahlstrom U, Forfang K, Kivikko M, Sarapohja T, Ullman B, Wikström G. Intravenous levosimendanvs. dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail. 2010; 12 (4): 404–10.